| scholarly article | Q13442814 |
| P50 | author | Benjamin D Philpot | Q86414336 |
| P2093 | author name string | Paul R Carney | |
| Sheryl S Moy | |||
| Viktoriya D Nikolova | |||
| Bin Gu | |||
| Manhua Zhu | |||
| Marie Rougié | |||
| Madison R Glass | |||
| P2860 | cites work | Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders | Q24623179 |
| Cannabinoids for pediatric epilepsy? Up in smoke or real science? | Q26770299 | ||
| Cannabinoids and Epilepsy. | Q27336451 | ||
| Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder | Q28071696 | ||
| Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression | Q30400868 | ||
| Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. | Q30440078 | ||
| Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats | Q33435013 | ||
| Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis. | Q33651529 | ||
| Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures | Q34269771 | ||
| Cannabinoids in the Treatment of Epilepsy | Q34493353 | ||
| Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q34557114 | ||
| Antianxiety effect of cannabidiol in the elevated plus-maze | Q34611017 | ||
| Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons | Q34763227 | ||
| Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb | Q35001117 | ||
| Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. | Q35720104 | ||
| Molecular Targets of Cannabidiol in Neurological Disorders | Q36157649 | ||
| GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility | Q36777517 | ||
| Behavior and neuropsychiatric manifestations in Angelman syndrome. | Q37284693 | ||
| Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats | Q37292275 | ||
| Epilepsy in patients with Angelman syndrome | Q37732476 | ||
| Clinical and genetic aspects of Angelman syndrome | Q37743131 | ||
| Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice | Q38641446 | ||
| Cannabidiol, neuroprotection and neuropsychiatric disorders | Q38723064 | ||
| Angelman syndrome - insights into a rare neurogenetic disorder | Q38951249 | ||
| Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | Q40151883 | ||
| Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases | Q40531740 | ||
| Analysis of EEG patterns and genotypes in patients with Angelman syndrome | Q44558820 | ||
| Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. | Q46005602 | ||
| Effect of epilepsy on autism symptoms in Angelman syndrome | Q47558616 | ||
| Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome | Q47668118 | ||
| Angelman syndrome: difficulties in EEG pattern recognition and possible misinterpretations. | Q48240930 | ||
| Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. | Q48354837 | ||
| Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice | Q48661423 | ||
| Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. | Q51438384 | ||
| Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsiv | Q56768080 | ||
| Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice | Q57797744 | ||
| A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel mutants | Q58741545 | ||
| A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans | Q59808748 | ||
| Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial | Q62867962 | ||
| Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes | Q62868102 | ||
| Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 | ||
| Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes | Q64040161 | ||
| Evolution of epilepsy and EEG findings in Angelman syndrome | Q73106976 | ||
| Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats | Q83864778 | ||
| Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test | Q85363821 | ||
| P433 | issue | 12 | |
| P921 | main subject | Angelman syndrome | Q535364 |
| P304 | page(s) | 5462-5467 | |
| P577 | publication date | 2019-12-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice | |
| P478 | volume | 129 |
| Q92921940 | Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? | cites work | P2860 |
Search more.